# Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1

> **NCT07024394** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 65 (estimated)

## Conditions studied

- Neurofibromatosis 1
- Plexiform Neurofibroma
- NF1

## Interventions

- **DRUG:** Luvometinib Tablets

## Key facts

- **NCT ID:** NCT07024394
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2029-09-23
- **Final completion:** 2029-09-23
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024394, "Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07024394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*